IPO周报 | 云迹科技港交所上市在即；企查查A股主板IPO获受理

Core Viewpoint - The article provides an overview of recent IPO activities in Hong Kong, the US, and A-shares, highlighting key companies and their market positions. Group 1: Changfeng Pharmaceutical - Changfeng Pharmaceutical officially listed on the Hong Kong Stock Exchange on October 8, 2025, under the stock code "2652" [3] - The global offering consisted of 41.198 million shares, with the Hong Kong public offering being oversubscribed by 6,697.80 times, marking the second-highest oversubscription since the revised pricing mechanism was implemented [3] - The company specializes in inhalation formulations and has a comprehensive product portfolio addressing significant clinical needs in respiratory diseases, including asthma and COPD [4] - The CEO emphasized the advantages of inhalation therapies and the company's commitment to innovation in this field, aiming to create long-term value for shareholders [4] Group 2: Yunji Technology - Yunji Technology plans to list on the Hong Kong Stock Exchange on October 16, 2025, with the stock code "2670" [6] - The company holds a leading position in China's robot service AI market, with a 6.3% market share and a 13.9% share in the hotel service sector [6] - Its products are used in over 34,000 hotels globally, and it has established partnerships with major hotel groups [6] - Financially, Yunji Technology's revenue grew from 161 million yuan in 2022 to 245 million yuan in 2024, with a compound annual growth rate of 23.2% [8] Group 3: Qichacha Technology - Qichacha's IPO application was accepted on October 10, 2025, aiming to list on the Shanghai Stock Exchange [10] - The company provides comprehensive business data services, helping users understand various commercial entities' credit and risk [10] - As of June 2023, Qichacha had over 150 million registered users and ranked second in market share among business data service providers in China [11] - The company reported revenues of 518 million yuan in 2022, with a net profit margin exceeding 45% [12] Group 4: InxMed Limited - InxMed Limited submitted its prospectus for listing on the Hong Kong Stock Exchange, focusing on improving cancer treatment paradigms [14] - The company is the only one in China with a selective FAK inhibitor in late-stage clinical trials, with a product pipeline that includes ifebemtinib [14][15] - Ifebemtinib is positioned to be a leading treatment option for various cancers, with regulatory recognition for its clinical potential [15] - InxMed has secured over 929 million yuan in investments from notable institutions, with a pre-IPO valuation of 306 million USD [16][17]